Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis - 15/10/16
, Bruce E. Strober, MD, PhD b, c, Peter R. Hansen, MD, PhD, DSc d, Ole Ahlehoff, MD, PhD e, Alexander Egeberg, MD, PhD d, f, Abrar A. Qureshi, MD, MPH g, h, Debbie Robertson, MS, RDN, LDN i, Hernan Valdez, MD j, Huaming Tan, PhD k, Robert Wolk, MD, PhD, DSc kAbstract |
Background |
Psoriasis is a systemic inflammatory condition that is associated with a higher risk of cardiovascular (CV) disease. Tofacitinib is being investigated as a treatment for psoriasis.
Objective |
We sought to evaluate the effects of tofacitinib on CV risk factors and major adverse CV events (MACEs) in patients with plaque psoriasis.
Methods |
Changes in select CV risk factors and the incidence rate (IR) of MACEs were evaluated in patients who were treated with tofacitinib.
Results |
Tofacitinib treatment was associated with small, dose-dependent increases in total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, while the total/HDL cholesterol ratio was unchanged. There were no changes in blood pressure and glycated hemoglobin levels; C-reactive protein levels decreased. The IRs of a MACE were low and similar for both tofacitinib doses. Among 3623 subjects treated with tofacitinib, the total patient-years of exposure was 5204, with a median follow-up of 527 days, and the IR of MACEs was 0.37 (95% confidence interval, 0.22-0.57) patients with events per 100 patient-years.
Limitations |
There was relatively short follow-up time for patients who had MACEs.
Conclusions |
While treatment with tofacitinib is associated with a small increase in cholesterol levels, the total/HDL cholesterol ratio does not change, there are no unfavorable changes in several CV risk factors, and the incidence of MACEs is low.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular outcomes, cardiovascular risk factors, major adverse cardiovascular events psoriasis, tofacitinib
Abbreviations used : BID, BP, CV, HbA1c, HDL, hsCRP, IR, LDL, LS, LTE, MACE, MI, OPT, PY, RA
Plan
| Supported by Pfizer. |
|
| Dr Wu has received research funding from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Coherus Biosciences, Dermira, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Regeneron, Sandoz, and Sun Pharmaceutical Industries and is a consultant for AbbVie, Amgen, Celgene, Dermira, Eli Lilly, Pfizer, Regeneron, and Sun Pharmaceutical Industries. Dr Strober has received honoraria for serving as a consultant, advisory board member, or speaker for AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Forward Pharma, Janssen, Leo, Maruho, Medac, Novartis, Pfizer, Stiefel/GlaxoSmithKline, Sun, and UCB; has received payments (to the University of Connecticut) as an investigator for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Xenoport, and Xoma; has received fees as a scientific director for the CORRONA Psoriasis Registry; and has received grant support (to the University of Connecticut for Fellowship Program) from AbbVie and Janssen. Dr Qureshi is a consultant for Abbvie, Amgen, the Centers for Disease Control and Prevention, Janssen, Merck, Novartis, and Pfizer, and is an investigator for Amgen. Dr Hansen received an unrestricted research grant from the LEO Foundation. Dr Ahlehoff received an unrestricted research grant from AbbVie and honoraria as a consultant or speaker from AbbVie, Janssen Pharmaceuticals, MSD, and Pfizer. Ms Robertson and Drs Valdez, Tan, and Wolk are employees and shareholders of Pfizer. Dr Egeberg is a former employee of Pfizer. |
Vol 75 - N° 5
P. 897-905 - novembre 2016 Retour au numéro
Article précédent
- HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series
- Ragna H. Thorleifsdottir, Sigrun L. Sigurdardottir, Bardur Sigurgeirsson, Jon H. Olafsson, Hannes Petersen, Martin I. Sigurdsson, Johann E. Gudjonsson, Andrew Johnston, Helgi Valdimarsson
- Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review
- Mary K. Hill, Azin Kheirandish Pishkenari, Taylor L. Braunberger, April W. Armstrong, Cory A. Dunnick
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?